Benztropine

Indications

• FDA-approved as an adjunct in all forms of parkinsonism, where it addresses tremor and rigidity more than bradykinesia.
• FDA-approved for drug-induced extrapyramidal disorders other than tardive dyskinesia, including antipsychotic parkinsonism and dystonia.
• FDA-approved for acute dystonic reactions, where a parenteral dose relieves oculogyric crisis or torticollis within about 15 minutes.
• Off-label short-term prophylaxis when starting a high-potency antipsychotic in a young man at high risk of acute dystonia.
• Off-label adjunct for antipsychotic-induced akathisia, although propranolol and benzodiazepines have better supporting evidence.
• It is not effective for tardive dyskinesia and frequently worsens it, so a VMAT2 inhibitor is the correct choice there.

Mechanism of action

• Antagonizes central muscarinic receptors, particularly M1, restoring the dopamine-acetylcholine balance disrupted by striatal D2 blockade.
• Because antipsychotic D2 blockade leaves cholinergic interneurons unopposed, muscarinic blockade relieves rigidity, tremor, and dystonia.
• Weak inhibition of presynaptic dopamine reuptake adds a small dopaminergic effect that contributes to its use in parkinsonism.
• Antihistaminic activity accounts for some sedation and for the overlap in effect with diphenhydramine in acute dystonia.
• Peripheral muscarinic blockade produces the dry mouth, blurred vision, constipation, urinary retention, and tachycardia seen clinically.

Pharmacokinetics

• Onset is within 15 minutes after intramuscular or intravenous administration and about 1 to 2 hours after an oral dose.
• Duration of action is long at roughly 24 hours, which allows convenient once or twice daily oral dosing.
• Human pharmacokinetic data are limited and the elimination half-life has never been well characterized in published studies.
• Metabolism is hepatic with a poorly defined enzymatic route, and elimination pathways have not been fully mapped.
• The long duration means anticholinergic effects can persist for a day or more after the last dose is taken.

Dosing

• Typical oral dosing for drug-induced parkinsonism is 1-2 mg/day, given once daily or divided, within a range of 0.5 to 6 mg per day.
• Acute dystonic reactions are treated with 1-2 mg IM or IV, repeated once if needed, followed by oral therapy for 1 to 2 weeks.
• Start older adults at 0.5 mg at bedtime and increase slowly, since confusion and urinary retention appear at low doses.
• The labeled maximum is 6 mg/day, but doses above 2 mg per day rarely add benefit and reliably add cognitive and peripheral effects.
• Attempt a taper after 3 months of stability, since many patients no longer need it once the antipsychotic dose has settled.
• Taper over 1 to 2 weeks rather than stopping abruptly, because cholinergic rebound can produce nausea, sweating, and worsened parkinsonism.

Adverse effects

• Dry mouth, blurred vision, constipation, and urinary hesitancy are dose-related and affect the majority of patients at higher doses.
• Cognitive impairment with memory and attention deficits is common and often unrecognized, and it worsens antipsychotic-related cognitive burden.
• Confusion, agitation, and frank anticholinergic delirium occur most often in older adults and in patients on other antimuscarinic drugs.
• Anhidrosis with heat intolerance can cause hyperthermia during exertion or hot weather, a risk shared with antipsychotics themselves.
• Tachycardia, urinary retention, and precipitation of narrow-angle glaucoma are the peripheral effects most likely to require stopping.
• Benztropine can be misused for its euphoriant and hallucinogenic effects at high doses, particularly in institutional settings.

Monitoring

• Review continued need at every visit and attempt a taper after the antipsychotic dose has been stable for about 3 months.
• Screen for constipation, urinary hesitancy, dry eyes, and blurred vision, all of which respond to dose reduction.
• Assess cognition and orientation at each visit in older patients, since anticholinergic delirium can develop insidiously.
• Check for narrow-angle glaucoma risk before starting and ask about eye pain, halos, or visual change during therapy.
• Track total anticholinergic burden across the medication list, including antihistamines, tricyclics, and bladder antimuscarinics.

Interactions

• Additive anticholinergic toxicity with tricyclic antidepressants, first-generation antihistamines, oxybutynin, and low-potency antipsychotics.
• Directly opposes cholinesterase inhibitors such as donepezil and rivastigmine, negating cognitive benefit in dementia.
• Slowed gastric emptying can alter absorption of other drugs, and reduced gut motility raises the risk of ileus with opioids.
• Combining with drugs that impair sweating, including antipsychotics and topiramate, increases the risk of heat stroke in hot conditions.
• Contraindicated in narrow-angle glaucoma and in children under 3 years, and used with great caution in myasthenia gravis and prostatic obstruction.

Special populations

• Pregnancy data are limited; use only when extrapyramidal symptoms clearly require treatment and prefer the lowest effective dose.
• Lactation data are sparse and anticholinergics may reduce milk supply, so monitor infant feeding and maternal milk production.
• Contraindicated under age 3 and used cautiously in older children, where dystonia can usually be managed with diphenhydramine.
• Older adults appear on Beers criteria for benztropine because of delirium, falls, and urinary retention risk; avoid where possible.
• No formal renal or hepatic dose adjustments exist, but reduce the dose when either organ system is significantly impaired.

Clinical pearls

• Benztropine worsens tardive dyskinesia; use a VMAT2 inhibitor instead and taper the anticholinergic.
• Reassess the need every few months; many patients stay on it for years without ongoing indication.
• For acute dystonia, 1-2 mg IM works within 15 minutes and should be followed by a week of oral dosing.